Share This Author
The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue
In vitro and in vivo methods demonstrate that designer methcathinone analogs are substrates for monoamine transporters, with a profile of transmitter-releasing activity comparable to MDMA.
Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive ‘Bath Salts’ Products
The data show that MDPV is a monoamine transporter blocker with increased potency and selectivity for catecholamines when compared with cocaine, and may provide a mechanism to explain the adverse effects observed in humans taking high doses of ‘bath salts’ preparations.
Reinforcing and neurochemical effects of the “bath salts” constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats
The hypothesis that elevations in extracellular 5-HT in the brain can dampen positive reinforcing effects of cathinone-type drugs is supported.
Analyses of second-generation 'legal highs' in the UK: initial findings.
It was found that 70% of NRG-1 andNRG-2 products appeared to contain a mixture of cathinones banned in April 2010 and rebranded as 'new' legal highs, rather than legal chemicals such as naphyrone as claimed by the retailers.
Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones.
- S. Brandt, S. Freeman, H. Sumnall, F. Measham, J. Cole
- ChemistryDrug Testing and Analysis
- 1 September 2011
The preparation of brominated precursors carrying the 3,4-methylenedioxyphenyl nucleus revealed extensive α,α-dibromination: the mass spectral and NMR data of these intermediates are also presented and discussed.
Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs.
Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.
- T. Passie, H. Emrich, M. Karst, S. Brandt, J. Halpern
- Psychology, BiologyDrug testing and analysis
- 1 July 2012
It is shown that recent studies provided supporting evidence that PTSD patients may be able to cope with their symptoms by using cannabis products and it is concluded that further studies are warranted in order to evaluate the therapeutic potential of cannabinoids in PTSD.
Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogues
The results suggest that these 1,2-diarylethylamines are relatively selective NMDAR antagonists with weak off-target inhibitory effects on dopamine and norepinephrine reuptake.
The new drug phenomenon.
This special issue provides a multidisciplinary snapshot of recent developments of the broader, arguably phenomenal, changes to the drugmarket that have occurred in the past decade related to the…
The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue